ReViral Revenue and Competitors
Estimated Revenue & Valuation
- ReViral's estimated annual revenue is currently $930k per year.
- ReViral's estimated revenue per employee is $155,000
Employee Data
- ReViral has 6 Employees.
- ReViral grew their employee count by -65% last year.
ReViral's People
| Name | Title | Email/Phone |
|---|---|---|
1 | HEAD OF PRECLINICAL DEVELOPMENT | Reveal Email/Phone |
2 | Director Finance | Reveal Email/Phone |
3 | CHIEF SCIENTIFIC OFFICER, FOUNDER | Reveal Email/Phone |
4 | CHIEF OPERATING OFFICER | Reveal Email/Phone |
5 | PROJECT DIRECTOR, FOUNDER | Reveal Email/Phone |
6 | CHIEF EXECUTIVE OFFICER | Reveal Email/Phone |
7 | Clinical Project Manager | Reveal Email/Phone |
8 | Medicinal Chemist | Reveal Email/Phone |
9 | Medicinal Chemist | Reveal Email/Phone |
ReViral Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ReViral?
ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-65%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ReViral News
Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a privately-held biotech...
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an...
ReViralwhich has operations in both London and Durham, NChas developed an RSV-focused pipeline led by sisunatovir (formerly RV521), an oral...
Other Companies in Stevenage
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A |
#2 | $1.3M | 15 | 0% | N/A |
#3 | $1.2M | 15 | 15% | N/A |
#4 | $2.3M | 23 | N/A | N/A |
#5 | $4.3M | 23 | -8% | N/A |